Source: International Congress 2019 – Clinical challenges in respiratory infection
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Gualano (Rome, Italy), P. Mencarini (Rome, Italy), M. Musso (Rome, Italy), S. Mosti (Rome, Italy), S. Murachelli (Rome, Italy), A. Cannas (Rome, Italy), A. Di Caro (Rome, Italy), D. Goletti (Rome, Italy), E. Girardi (Rome, Italy), F. Palmieri (Rome, Italy). Putting in Harm to cure: Drug related adverse events do not affect outcome of patients receiving treatment for Multidrug-Resistant Tuberculosis. 4567

Member's Comments

No comment yet.

Related content which might interest you: Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Risk for adverse outcomes in asthma: Assess to impress! Source: International Congress 2016 – Phenotyping and monitoring airway diseases Year: 2016 Impact of drug injection using on TB-AIDS treatment outcomes Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013 Preventing MDRTB in Europe: Drug sensitivities received after the initial phase of treatment Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Risk of serious adverse reactions during the treatment of new tuberculosis patients Source: Annual Congress 2012 - Tuberculosis: clinical findings II Year: 2012 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Metrics of salbutamol use as predictors of future adverse outcomes in asthma Source: Annual Congress 2013 –Quality of diagnosis and assessment in primary care Year: 2013 Latent TB infection: Patient choices and completion of treatment Source: International Congress 2016 – Treatment management options and costs: vitamin D, Matrix metalloproteinases (MMPs), nutrition, and human genetics Year: 2016 Recurrent TB in Ireland is predominantly due to relapsed infection and is frequently associated with poor compliance with therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Tuberculosis and intravenous drug users, impact of proximity measures in screening and treatment Source: International Congress 2015 – Screening strategies in TB Year: 2015 Predictors of hepatotoxicity among patients with tuberculosis treated with antituberculous medication Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016 Impact of tobacco smoking on anti-tuberculosis treatment outcomes Source: Annual Congress 2013 –Tobacco use in different countries: crisis to disease Year: 2013 Late Breaking Abstract - Comparative analysis of effectiveness of Asthma Control Test-guided treatment versus usual care in patients with asthma from China Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 The side effects, the outcome and the mortality of anti-tuberculosis treatment in dialyzed patients: A 10-year retrospective analysis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Treatment outcomes of new TB cases among children in Russia Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Efficacy and safety of modified anti-tubercular treatment(ATT) regimens in treatment of tuberculosis(TB) in patients with underlying chronic liver disease(CLD) Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Patients over 35 years experience more side-effects during latent TB treatment: Experience from an urban hospital with a high incidence of Tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Ten-year projected outcomes associated with increased use of triple therapies in UK patients with COPD using the COPD Health Outcome Policy and INtervention (CHOPIN) model Source: Virtual Congress 2021 – COPD pharmacology: from basic science to real-world data Year: 2021 Interim report: The effectiveness of smoking cessation in tuberculosis patients and its effective factor Source: International Congress 2016 – Smoking cessation strategies Year: 2016